{"hands_on_practices": [{"introduction": "A compound's ability to reach its target is governed by its physicochemical properties. This exercise [@problem_id:5021279] provides essential practice in calculating the distribution coefficient at physiological pH, $\\log D_{7.4}$, which is a more accurate predictor of a drug's behavior in the body than the simpler partition coefficient, $\\log P$. By combining this calculated lipophilicity with the Topological Polar Surface Area (TPSA), you will learn to make qualitative predictions about a molecule's potential to cross the blood-brain barrier, a critical step in designing CNS-active drugs.", "problem": "In hit-to-lead progression and lead optimization within translational medicine, physicochemical properties such as lipophilicity and ionization determine the distribution coefficient at physiological pH, which in turn influences Blood-Brain Barrier (BBB) permeability and Central Nervous System (CNS) exposure. Consider a monoprotic weak base that partitions between aqueous buffer at pH $7.4$ and octanol, characterized by a base-10 octanol/water partition coefficient $\\log_{10} P = 3.0$ at infinite dilution and an acid dissociation constant with $pK_{a} = 8.0$. Assume that only the neutral base form contributes meaningfully to the octanol phase while the protonated (ionized) form remains in the aqueous phase. Starting from the Hendersonâ€“Hasselbalch relationship for the base and the definition of the octanol/water partition coefficient and distribution coefficient, derive the expression for the distribution coefficient at pH $7.4$, denoted $\\log_{10} D_{7.4}$, and compute its value. Then, using the Topological Polar Surface Area (TPSA) of $65\\,\\text{\\AA}^{2}$, infer the qualitative impact on CNS penetration across the BBB in the context of lead optimization. Express the final numerical answer for $\\log_{10} D_{7.4}$ as a dimensionless quantity and round your answer to four significant figures.", "solution": "The problem requires the derivation and calculation of the distribution coefficient, $\\log_{10} D_{7.4}$, for a monoprotic weak base at physiological pH, and a subsequent qualitative assessment of its potential for Central Nervous System (CNS) penetration based on the calculated $\\log_{10} D_{7.4}$ and a given Topological Polar Surface Area (TPSA).\n\nFirst, we establish the relevant chemical equilibria and definitions. Let the weak base be denoted by $B$ and its protonated (conjugate acid) form by $BH^+$. The acid dissociation equilibrium for the conjugate acid in the aqueous phase is:\n$$BH^+_{aq} \\rightleftharpoons B_{aq} + H^+_{aq}$$\nThe acid dissociation constant, $K_a$, for this equilibrium is defined as:\n$$K_a = \\frac{[B]_{aq}[H^+]_{aq}}{[BH^+]_{aq}}$$\nThe $pK_a$ is defined as $pK_a = -\\log_{10}(K_a)$. The relationship between $pH$, $pK_a$, and the concentrations of the acidic and basic forms is given by the Henderson-Hasselbalch equation. We can rearrange the $K_a$ expression:\n$$\\log_{10}(K_a) = \\log_{10}\\left(\\frac{[B]_{aq}}{[BH^+]_{aq}}\\right) + \\log_{10}([H^+]_{aq})$$\n$$-pK_a = \\log_{10}\\left(\\frac{[B]_{aq}}{[BH^+]_{aq}}\\right) - pH$$\n$$pH - pK_a = \\log_{10}\\left(\\frac{[B]_{aq}}{[BH^+]_{aq}}\\right)$$\nFrom this, we can express the ratio of the ionized form to the neutral form:\n$$\\frac{[B]_{aq}}{[BH^+]_{aq}} = 10^{(pH - pK_a)}$$\n$$\\frac{[BH^+]_{aq}}{[B]_{aq}} = 10^{(pK_a - pH)}$$\n\nNext, we define the partition coefficient, $P$, and the distribution coefficient, $D$. The partition coefficient, $P$, describes the partitioning of the single, neutral species between two immiscible phases (octanol and water). It is given by:\n$$P = \\frac{[B]_{oct}}{[B]_{aq}}$$\nThe problem states that $\\log_{10} P = 3.0$, which implies $P = 10^{3.0}$.\n\nThe distribution coefficient, $D$, accounts for all species of the compound (neutral and ionized) in the aqueous phase. Based on the problem's assumption that only the neutral form $B$ enters the octanol phase, $D$ is defined as:\n$$D = \\frac{[\\text{Total concentration in octanol}]}{[\\text{Total concentration in aqueous}]} = \\frac{[B]_{oct}}{[B]_{aq} + [BH^+]_{aq}}$$\nTo derive an expression for $D$ in terms of $P$, $pH$, and $pK_a$, we substitute $[B]_{oct} = P \\cdot [B]_{aq}$ into the expression for $D$:\n$$D = \\frac{P \\cdot [B]_{aq}}{[B]_{aq} + [BH^+]_{aq}}$$\nWe can simplify this by dividing the numerator and denominator by $[B]_{aq}$:\n$$D = \\frac{P}{1 + \\frac{[BH^+]_{aq}}{[B]_{aq}}}$$\nNow, we substitute the ratio derived from the Henderson-Hasselbalch relationship, $\\frac{[BH^+]_{aq}}{[B]_{aq}} = 10^{(pK_a - pH)}$:\n$$D = \\frac{P}{1 + 10^{(pK_a - pH)}}$$\nThis is the general expression for the distribution coefficient of a monoprotic weak base. To find the expression for $\\log_{10} D$, we take the base-10 logarithm of both sides:\n$$\\log_{10} D = \\log_{10}\\left(\\frac{P}{1 + 10^{(pK_a - pH)}}\\right)$$\n$$\\log_{10} D = \\log_{10} P - \\log_{10}\\left(1 + 10^{(pK_a - pH)}\\right)$$\nThis is the required derived expression.\n\nNow, we compute the numerical value for $\\log_{10} D_{7.4}$ using the provided data: $\\log_{10} P = 3.0$, $pK_a = 8.0$, and $pH = 7.4$.\n$$\\log_{10} D_{7.4} = 3.0 - \\log_{10}\\left(1 + 10^{(8.0 - 7.4)}\\right)$$\n$$\\log_{10} D_{7.4} = 3.0 - \\log_{10}\\left(1 + 10^{0.6}\\right)$$\nWe calculate the value of the term in the logarithm:\n$$10^{0.6} \\approx 3.98107$$\n$$1 + 10^{0.6} \\approx 1 + 3.98107 = 4.98107$$\nNow, we compute the logarithm of this value:\n$$\\log_{10}(4.98107) \\approx 0.69732$$\nFinally, we substitute this back into the equation for $\\log_{10} D_{7.4}$:\n$$\\log_{10} D_{7.4} \\approx 3.0 - 0.69732 = 2.30268$$\nRounding the result to four significant figures as requested, we get:\n$$\\log_{10} D_{7.4} \\approx 2.303$$\n\nFor the final part of the problem, we must infer the qualitative impact on CNS penetration. In lead optimization for CNS-targeted drugs, two key physicochemical parameters are the distribution coefficient at physiological pH, $\\log_{10} D_{7.4}$, and the Topological Polar Surface Area, TPSA.\n1.  **$\\log_{10} D_{7.4}$**: This parameter reflects the effective lipophilicity of the compound. For efficient transport across the lipidic Blood-Brain Barrier (BBB), a compound must have sufficient lipophilicity, but excessive lipophilicity can lead to non-specific binding, rapid metabolism, or poor aqueous solubility. A widely accepted optimal range for CNS penetration is typically $1 < \\log_{10} D_{7.4} < 3$. Our calculated value of $\\log_{10} D_{7.4} \\approx 2.303$ falls squarely within this optimal range.\n2.  **TPSA**: This parameter correlates with the molecule's hydrogen bonding capacity and its ability to permeate membranes. High TPSA values are associated with poor membrane permeability. For good BBB penetration, a TPSA below $90\\,\\text{\\AA}^{2}$ is generally recommended, with values below $70\\,\\text{\\AA}^{2}$ being more favorable. The given value is $TPSA = 65\\,\\text{\\AA}^{2}$, which is well below these established cutoffs.\n\nGiven that both the calculated effective lipophilicity ($\\log_{10} D_{7.4} \\approx 2.303$) and the given polarity attribute ($TPSA = 65\\,\\text{\\AA}^{2}$) fall within their respective optimal ranges for crossing the BBB, the qualitative inference is that the compound possesses a physicochemical profile highly favorable for achieving significant CNS exposure. This makes it a promising candidate for a CNS-acting drug if that is the therapeutic goal, or a potential liability if CNS side effects are to be avoided.", "answer": "$$\\boxed{2.303}$$", "id": "5021279"}, {"introduction": "Effective lead optimization requires improving potency without introducing undesirable properties. This practice [@problem_id:5021242] introduces the concept of Ligand Lipophilicity Efficiency (LipE), a key metric used to evaluate the quality of a chemical modification. By analyzing a matched molecular pair, you will quantify how a specific structural change impacts both potency and lipophilicity, learning to distinguish between productive and counterproductive optimization strategies.", "problem": "In hit-to-lead progression, matched molecular pair analysis is used to quantify how a specific, single-atom or single-group substitution perturbs both potency and physicochemical properties across closely related chemotypes. Consider two independent series of matched pairs that differ only by a para-substituent on a phenyl ring, switching between para-fluoro and para-methyl. For each series, the experimental observation for the substitution from para-methyl to para-fluoro is that the potency on a base-$10$ logarithmic scale ($pIC_{50}$) increases by $+0.3$, and the distribution coefficient on a base-$10$ logarithmic scale ($\\log D$) at physiological pH increases by $+0.5$. \n\nStarting from the standard definition of $pIC_{50}$ as $-\\log_{10}$ of molar $IC_{50}$ and the conventional use of a lipophilicity-normalized potency efficiency metric that subtracts a lipophilicity term from a potency term, derive an expression for the change in Ligand Lipophilicity Efficiency (LipE) under a matched-pair transformation in terms of changes in $pIC_{50}$ and $\\log D$. Then, calculate the numerical value of this change for each of the two series described.\n\nProvide your final answer as a row matrix containing the two values (Series A and Series B, in that order). Provide exact values; do not round. The quantities are dimensionless; do not include units in the final answer.", "solution": "The problem requires the derivation of an expression for the change in Ligand Lipophilicity Efficiency and its calculation for two independent series of chemical compounds undergoing a specific structural modification.\n\nFirst, we must formalize the definition of Ligand Lipophilicity Efficiency (LipE) based on the problem description. The problem states that LipE is a \"lipophilicity-normalized potency efficiency metric that subtracts a lipophilicity term from a potency term.\" The potency term is given as $pIC_{50}$, which is on a base-$10$ logarithmic scale. The lipophilicity term is given as the distribution coefficient on a base-$10$ logarithmic scale, $\\log D$. Therefore, the definition of LipE can be written as:\n$$\n\\text{LipE} = pIC_{50} - \\log D\n$$\n\nNext, we consider a transformation from an initial state (State $1$) to a final state (State $2$). In this problem, State $1$ corresponds to the compound with a para-methyl substituent, and State $2$ corresponds to the compound with a para-fluoro substituent. The LipE for each state is:\n$$\n\\text{LipE}_1 = pIC_{50,1} - \\log D_1\n$$\n$$\n\\text{LipE}_2 = pIC_{50,2} - \\log D_2\n$$\n\nThe change in LipE, denoted as $\\Delta \\text{LipE}$, is the difference between the LipE of the final state and the initial state:\n$$\n\\Delta \\text{LipE} = \\text{LipE}_2 - \\text{LipE}_1\n$$\nSubstituting the expressions for $\\text{LipE}_1$ and $\\text{LipE}_2$:\n$$\n\\Delta \\text{LipE} = (pIC_{50,2} - \\log D_2) - (pIC_{50,1} - \\log D_1)\n$$\nBy rearranging the terms, we can group the changes in potency and lipophilicity:\n$$\n\\Delta \\text{LipE} = (pIC_{50,2} - pIC_{50,1}) - (\\log D_2 - \\log D_1)\n$$\nThe terms in the parentheses represent the change in $pIC_{50}$ ($\\Delta pIC_{50}$) and the change in $\\log D$ ($\\Delta \\log D$), respectively. Thus, the general expression for the change in LipE under a matched-pair transformation is:\n$$\n\\Delta \\text{LipE} = \\Delta pIC_{50} - \\Delta \\log D\n$$\nThis is the derived expression for the change in Ligand Lipophilicity Efficiency in terms of the changes in $pIC_{50}$ and $\\log D$.\n\nNow, we must calculate the numerical value of $\\Delta \\text{LipE}$ for the two series described in the problem. The problem states that for the substitution from para-methyl to para-fluoro, the experimental observations are the same for both Series A and Series B. The given changes are:\n- The change in potency, $\\Delta pIC_{50} = +0.3$.\n- The change in lipophilicity, $\\Delta \\log D = +0.5$.\n\nFor Series A, we apply the derived formula:\n$$\n\\Delta \\text{LipE}_A = \\Delta pIC_{50} - \\Delta \\log D = 0.3 - 0.5 = -0.2\n$$\n\nFor Series B, the experimental observations are identical, so the calculation is also identical:\n$$\n\\Delta \\text{LipE}_B = \\Delta pIC_{50} - \\Delta \\log D = 0.3 - 0.5 = -0.2\n$$\n\nThe problem asks for the final answer as a row matrix containing the two values for Series A and Series B, in that order. Both values are $-0.2$. These quantities are dimensionless as they are differences of logarithmic values.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n-0.2 & -0.2\n\\end{pmatrix}\n}\n$$", "id": "5021242"}, {"introduction": "Choosing the single best compound to advance from a pool of candidates involves balancing multiple, often competing, attributes. Multi-Parameter Optimization (MPO) offers a quantitative framework for this complex decision-making process by consolidating diverse data into a single desirability score. This final exercise [@problem_id:5021305] simulates this integrative process, challenging you to compute an MPO score and demonstrating how modern drug discovery programs systematically rank compounds for progression.", "problem": "In hit-to-lead progression within translational medicine, multi-parameter decision-making often aggregates several property-specific desirability functions into a single Multi-Parameter Optimization (MPO) score. Consider an additive multi-attribute utility framework grounded in Multi-Attribute Utility Theory (MAUT), where attributes are assumed to be mutually utility independent and each property is transformed into a unitless desirability value on the interval $\\left[0,1\\right]$. Let the overall utility be additive with weights that sum to unity. Under these assumptions, the MPO score is identified with the overall utility.\n\nA candidate compound has the following properties: potency $\\left(pIC_{50} = 7.5\\right)$, lipophilicity $\\left(\\log D_{7.4} = 1.8\\right)$, Total Polar Surface Area (TPSA) $\\left(70\\,\\text{\\AA}^2\\right)$, acid dissociation constant $\\left(pK_{a} = 7.2\\right)$, and no structural alerts. Suppose these properties have already been mapped to desirability values using standardized, monotone desirability functions to yield the set $\\{d_{i}\\}$ given by $d_{1} = 0.9$, $d_{2} = 0.8$, $d_{3} = 0.7$, $d_{4} = 0.8$, and $d_{5} = 1.0$. Assume equal importance across the five attributes.\n\nStarting from the axioms of Multi-Attribute Utility Theory (MAUT) that justify an additive representation when attributes are mutually utility independent and when single-attribute utilities are affine-scaled to $\\left[0,1\\right]$, derive the expression for the MPO score under equal weights that sum to unity, and then compute the numerical MPO score for this compound using the provided $\\{d_{i}\\}$. Express the final MPO score as a unitless fraction between $0$ and $1$, and round your answer to three significant figures.", "solution": "The problem asks for the derivation and calculation of a Multi-Parameter Optimization (MPO) score based on the principles of an additive multi-attribute utility framework. The foundational axiom of Multi-Attribute Utility Theory (MAUT) that permits an additive representation is the condition of mutual utility independence among the attributes. When this condition holds, the overall utility function $U$ for a set of attributes $\\mathbf{x} = (x_1, x_2, \\ldots, x_n)$ can be expressed as an additive combination of the individual single-attribute utility functions $u_i(x_i)$:\n$$U(x_1, x_2, \\ldots, x_n) = \\sum_{i=1}^{n} w_i u_i(x_i)$$\nHere, $w_i$ represents the weight or importance of the $i$-th attribute, and the weights are normalized to sum to unity:\n$$\\sum_{i=1}^{n} w_i = 1$$\nThe individual utility functions $u_i(x_i)$ are scaled to a common interval, which in this problem is specified as $[0, 1]$.\n\nThe problem identifies the overall utility $U$ with the MPO score and the scaled single-attribute utilities $u_i(x_i)$ with the given desirability values $d_i$. Therefore, we can write the MPO score as:\n$$\\text{MPO} = \\sum_{i=1}^{n} w_i d_i$$\nThe problem specifies that there are $n=5$ attributes for the candidate compound. These are potency, lipophilicity, TPSA, acid dissociation constant, and absence of structural alerts. The corresponding desirability values $\\{d_i\\}$ are given as $d_{1} = 0.9$, $d_{2} = 0.8$, $d_{3} = 0.7$, $d_{4} = 0.8$, and $d_{5} = 1.0$.\n\nThe problem also states that there is \"equal importance across the five attributes.\" This implies that all weights are equal:\n$$w_1 = w_2 = w_3 = w_4 = w_5 = w$$\nUsing the normalization condition that the weights must sum to unity:\n$$\\sum_{i=1}^{5} w_i = w_1 + w_2 + w_3 + w_4 + w_5 = 5w = 1$$\nSolving for $w$, we find the weight for each attribute:\n$$w = \\frac{1}{5} = 0.2$$\nNow, we can substitute this equal weight back into the general MPO expression to derive the specific formula for this case. For $n$ attributes with equal weights, the weight for each is $w_i = \\frac{1}{n}$. The MPO score becomes:\n$$\\text{MPO} = \\sum_{i=1}^{n} \\left(\\frac{1}{n}\\right) d_i = \\frac{1}{n} \\sum_{i=1}^{n} d_i$$\nThis derived expression shows that under the assumption of equal importance, the MPO score is simply the arithmetic mean of the individual desirability scores.\n\nWe now compute the numerical MPO score for the given compound using the provided desirability values and $n=5$:\n$$\\text{MPO} = \\frac{1}{5} (d_1 + d_2 + d_3 + d_4 + d_5)$$\nSubstituting the values:\n$$\\text{MPO} = \\frac{1}{5} (0.9 + 0.8 + 0.7 + 0.8 + 1.0)$$\nFirst, we sum the desirability scores:\n$$\\sum_{i=1}^{5} d_i = 0.9 + 0.8 + 0.7 + 0.8 + 1.0 = 4.2$$\nNext, we divide by the number of attributes, $n=5$:\n$$\\text{MPO} = \\frac{4.2}{5} = 0.84$$\nThe problem requires the answer to be rounded to three significant figures. The calculated value $0.84$ has two significant figures. To express it with three, we add a trailing zero.\n$$\\text{MPO} = 0.840$$\nThis final value is a unitless fraction between $0$ and $1$, as required.", "answer": "$$\\boxed{0.840}$$", "id": "5021305"}]}